Nuvalent, Inc. completed a merger on July 15, 2026, becoming a wholly-owned subsidiary of its parent company. All shareholders received cash for their shares at the offer price, and all outstanding stock options and restricted stock units were cancelled and exchanged for cash. The total equity value of the transaction is approximately $10.6 billion. The company will be delisted from Nasdaq and will terminate its SEC reporting obligations.
Who are the top institutional investors holding NUVALENT INC-A (NUVL)?
Major stakeholders currently include Deerfield Management Company, L.p. ($1.8B), FMR LLC ($950.2M), Paradigm Biocapital Advisors LP ($545.5M). Based on the latest 13F filings, there are a total of 264 tracked investment funds and institutions maintaining positions in NUVL.
What is the overall institutional sentiment toward NUVL recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $264.6M, driven by 158 managers accumulating shares while 94 reduced their exposure.
Which institutions have been selling or reducing their NUVL positions?
In the latest period, 70 funds trimmed their holdings, and 24 managers completely exited their positions. The aggregate reported sell value was $2.7B.
Are there any notable investors adding NUVL to their portfolios?
Yes, buying activity remains notable. 47 institutions opened new positions in {ticker}, and 111 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.7B.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter